Merck Snaps Up Small Startup in $208M Deal, Seeks to Improve Safety of ADCs 4/8/2024

BMS Sees Early ROI for $14B Karuna Buy with Phase III Schizophrenia Win 4/8/2024

ACC24 Roundup: Novo, Ionis Tout Cardio Victories and Boehringer, Lilly Disappoint 4/8/2024

5 Successful Phase III Oncology Trials in Q1 4/8/2024

The Next Wave of ADCs Could Treat Evasive Solid Tumors 4/8/2024

AstraZeneca, Daiichi Sankyo Win First Tumor-Agnostic HER2 FDA Approval for Enhertu 4/8/2024

FDA Again Rejects Supernus Drug-Device Combo for Parkinson’s Disease 4/8/2024

Opinion: The Next Generation of ADCs Will Improve Cancer Treatment 4/8/2024

Fewer side effects, improved chances of healing: the goal of precision medicine is to provide patients with the most individualized treatment possible. This requires a precise understanding of what is happening at the cellular level. For the first time, researchers at the Technical University of Munich (TUM) have now succeeded in mapping the interactions of 144 active substances with around 8,000 proteins. The results could help to identify previously unknown potential benefits of existing drugs.

GSK, Moderna and Pfizer are all looking at potential respiratory syncytial virus vaccine sales slumps thanks to recently updated CDC guidelines regarding the use of RSV shots in seniors.

Vividion Therapeutics, Inc. (Vividion), a clinical stage biopharmaceutical company utilizing novel discovery technologies to unlock high-value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, announced it will expand its global innovation capabilities with a new research and development (R&D) center and corporate headquarters in San Diego, California. Vividion is a wholly owned and independently operating subsidiary of Bayer AG.